Literature DB >> 28684612

The Effect of Iron Status on Risk of Coronary Artery Disease: A Mendelian Randomization Study-Brief Report.

Dipender Gill1, Fabiola Del Greco M2, Ann P Walker2, Surjit K S Srai2, Michael A Laffan2, Cosetta Minelli2.   

Abstract

OBJECTIVE: Iron status is a modifiable trait that has been implicated in cardiovascular disease. This study uses the Mendelian randomization technique to investigate whether there is any causal effect of iron status on risk of coronary artery disease (CAD). APPROACH AND
RESULTS: A 2-sample Mendelian randomization approach is used to estimate the effect of iron status on CAD risk. Three loci (rs1800562 and rs1799945 in the HFE gene and rs855791 in TMPRSS6) that are each associated with serum iron, transferrin saturation, ferritin, and transferrin in a pattern suggestive of an association with systemic iron status are used as instruments. SNP (single-nucleotide polymorphism)-iron status association estimates are based on a genome-wide association study meta-analysis of 48 972 individuals. SNP-CAD estimates are derived by combining the results of a genome-wide association study meta-analysis of 60 801 CAD cases and 123 504 controls with those of a meta-analysis of 63 746 CAD cases and 130 681 controls obtained from Metabochip and genome-wide association studies. Combined Mendelian randomization estimates are obtained for each marker by pooling results across the 3 instruments. We find evidence of a protective effect of higher iron status on CAD risk (iron odds ratio, 0.94 per SD unit increase; 95% confidence interval, 0.88-1.00; P=0.039; transferrin saturation odds ratio, 0.95 per SD unit increase; 95% confidence interval, 0.91-0.99; P=0.027; log-transformed ferritin odds ratio, 0.85 per SD unit increase; 95% confidence interval, 0.73-0.98; P=0.024; and transferrin odds ratio, 1.08 per SD unit increase; 95% confidence interval, 1.01-1.16; P=0.034).
CONCLUSIONS: This Mendelian randomization study supports the hypothesis that higher iron status reduces CAD risk. These findings may highlight a therapeutic target.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  cardiovascular diseases; coronary artery disease; iron

Mesh:

Substances:

Year:  2017        PMID: 28684612     DOI: 10.1161/ATVBAHA.117.309757

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  29 in total

1.  Hepcidin Deficiency Protects Against Atherosclerosis.

Authors:  Rajeev Malhotra; Florian Wunderer; Hanna J Barnes; Aranya Bagchi; Mary D Buswell; Caitlin D O'Rourke; Charles L Slocum; Clara D Ledsky; Kathryn M Peneyra; Haakon Sigurslid; Benjamin Corman; Kimberly B Johansson; David K Rhee; Kenneth D Bloch; Donald B Bloch
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-02       Impact factor: 8.311

2.  Ironing-Out the Role of Hepcidin in Atherosclerosis.

Authors:  Liang Guo; Atsushi Sakamoto; Anne Cornelissen; Charles C Hong; Aloke V Finn
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

Review 3.  Pathological Roles of Iron in Cardiovascular Disease.

Authors:  Motoi Kobayashi; Tomohiro Suhara; Yuichi Baba; Nicholas K Kawasaki; Jason K Higa; Takashi Matsui
Journal:  Curr Drug Targets       Date:  2018       Impact factor: 3.465

Review 4.  The role of hepcidin and iron homeostasis in atherosclerosis.

Authors:  Florian Wunderer; Lisa Traeger; Haakon H Sigurslid; Patrick Meybohm; Donald B Bloch; Rajeev Malhotra
Journal:  Pharmacol Res       Date:  2020-01-25       Impact factor: 7.658

5.  Genetic support of a causal relationship between iron status and atrial fibrillation: a Mendelian randomization study.

Authors:  Tianyi Wang; Jun Cheng; Yanggan Wang
Journal:  Genes Nutr       Date:  2022-05-30       Impact factor: 4.423

6.  Causal Relationship of Genetically Predicted Serum Micronutrients Levels With Sarcopenia: A Mendelian Randomization Study.

Authors:  Tingting Sha; Wei Li; Hongyi He; Jing Wu; Yilun Wang; Hui Li
Journal:  Front Nutr       Date:  2022-06-22

7.  Mendelian randomization highlights insomnia as a risk factor for pain diagnoses.

Authors:  Martin Broberg; Juha Karjalainen; Hanna M Ollila
Journal:  Sleep       Date:  2021-07-09       Impact factor: 5.849

8.  Genetically predicted circulating concentrations of micronutrients and risk of breast cancer: A Mendelian randomization study.

Authors:  Nikos Papadimitriou; Niki Dimou; Dipender Gill; Ioanna Tzoulaki; Neil Murphy; Elio Riboli; Sarah J Lewis; Richard M Martin; Marc J Gunter; Konstantinos K Tsilidis
Journal:  Int J Cancer       Date:  2020-08-25       Impact factor: 7.396

9.  Translating GWAS Findings to Novel Therapeutic Targets for Coronary Artery Disease.

Authors:  Le Shu; Montgomery Blencowe; Xia Yang
Journal:  Front Cardiovasc Med       Date:  2018-05-30

10.  Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis.

Authors:  Constantinos A Parisinos; Henry R Wilman; E Louise Thomas; Matt Kelly; Rowan C Nicholls; John McGonigle; Stefan Neubauer; Aroon D Hingorani; Riyaz S Patel; Harry Hemingway; Jimmy D Bell; Rajarshi Banerjee; Hanieh Yaghootkar
Journal:  J Hepatol       Date:  2020-04-02       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.